The angiotensin receptor–neprilysin inhibitor (LCZ696) was compared to the ACE inhibitor Enalapril in patients with systolic heart failure. All-cause mortality fell 16% on the novel agent. Follow-up averaged about 27 months. The study was published in the New England Journal of Medicine and the accompanying editorial stated the new agent "may prove to be the first disruptive agent to the heart-failure treatment algorithm, which has remained essentially unchanged for a decade".